JP2016514159A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514159A5
JP2016514159A5 JP2016502219A JP2016502219A JP2016514159A5 JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5 JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
heteroaryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514159A (ja
JP6276378B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026710 external-priority patent/WO2014151945A1/en
Publication of JP2016514159A publication Critical patent/JP2016514159A/ja
Publication of JP2016514159A5 publication Critical patent/JP2016514159A5/ja
Application granted granted Critical
Publication of JP6276378B2 publication Critical patent/JP6276378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502219A 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤 Expired - Fee Related JP6276378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783563P 2013-03-14 2013-03-14
US61/783,563 2013-03-14
PCT/US2014/026710 WO2014151945A1 (en) 2013-03-14 2014-03-13 Histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016514159A JP2016514159A (ja) 2016-05-19
JP2016514159A5 true JP2016514159A5 (enExample) 2017-02-16
JP6276378B2 JP6276378B2 (ja) 2018-02-07

Family

ID=51529949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502219A Expired - Fee Related JP6276378B2 (ja) 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤

Country Status (7)

Country Link
US (5) US9527829B2 (enExample)
EP (1) EP2969007B1 (enExample)
JP (1) JP6276378B2 (enExample)
AU (1) AU2014236711A1 (enExample)
CA (1) CA2903081A1 (enExample)
ES (1) ES2731773T3 (enExample)
WO (1) WO2014151945A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2731773T3 (es) * 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
US10414750B2 (en) 2014-07-03 2019-09-17 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
SG11201702108PA (en) * 2014-09-16 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
WO2016112251A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017143011A1 (en) * 2016-02-16 2017-08-24 Chrysalis, Inc. Histone demethylase inhibitors
EP3436445B1 (en) * 2016-03-15 2023-09-06 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
KR102202984B1 (ko) 2016-05-27 2021-01-13 길리애드 사이언시즈, 인코포레이티드 Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN106543092B (zh) * 2016-10-14 2019-05-17 华东师范大学 1,5-二芳香基-1,2,4-三氮唑类化合物及其制药用途
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ, インコーポレイテッド Hpk1阻害活性を有する置換6-アザベンゾイミダゾール化合物
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP7237311B2 (ja) * 2019-06-06 2023-03-13 京都府公立大学法人 化合物、医薬組成物、kdm5c阻害剤及び抗うつ剤
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
EP4192474B1 (en) 2020-08-07 2025-09-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
DE60133758T2 (de) 2000-10-26 2009-07-02 Amgen Inc., Thousand Oaks Antiphlogistische mittel
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2007071653A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
EP2090570B1 (en) * 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
AU2008242720A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
EP2451790A4 (en) * 2009-07-07 2012-12-26 Anthem Biosciences Private Ltd INHIBITORS OF HISTONE DEACETYLASE
EA020153B1 (ru) 2009-11-10 2014-09-30 Пфайзер Инк. N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ
WO2011089995A1 (ja) * 2010-01-21 2011-07-28 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたhdac8阻害剤
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
SG11201702108PA (en) 2014-09-16 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors

Similar Documents

Publication Publication Date Title
JP2016514159A5 (enExample)
JP2016501882A5 (enExample)
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
JP2016503799A5 (enExample)
JP2017527590A5 (enExample)
JP2016505614A5 (enExample)
JP2013532687A5 (enExample)
CY1118340T1 (el) Αναστολεις κινασης
JP2015024998A5 (enExample)
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
JP2015522045A5 (enExample)
JP2017508782A5 (enExample)
JP2018531941A5 (enExample)
JP2011529054A5 (enExample)
JP2011518833A5 (enExample)
JP2017501237A5 (enExample)
JP2013532130A5 (enExample)
JP2015199738A5 (enExample)
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
JP2014526533A5 (enExample)
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
JP2017538836A5 (enExample)
JP2016532632A5 (enExample)